ASCENDEX LISTS BATTLE OF GUARDIANS TOKEN, BGS

Singapore, Jan 14 (Bernama-GLOBE NEWSWIRE) -- AscendEX is thrilled to announce the listing of the Battle of Guardians Share Token (BGS) under the trading pair BGS/USDT starting on January 14th at 2 p.m. UTC. 

Battle of Guardians (BOG) is a real-time, multiplayer NFT fighting game that allows players to utilize their NFT assets as fighting avatars in an all-out battle of skills, where heightened skill is recognized with in-game rewards. Developed in Unreal Engine and built atop the Solana Network, BOG was designed with multiplayer capabilities that allow global players to engage in fierce, multi-realm battles in the expansive Sci-Fi game ecosystem. The project currently offers a selection of 30 unique NFTs and is equipped with an NFT Synthesis feature that allows players to upgrade the tier of their fighting avatars. BOG is being developed for PC-based gaming, with iOS and Android cross-platform multiplayer features becoming available in the future.

Recently, the play-to-earn model has become the standard for new-to-market, blockchain-based gaming ecosystems. The convergence of gaming and finance through NFTs has become an exciting and interactive way for players of games, and owners of NFTs, to earn real-world rewards. BOG aims to emphasize the “play” aspect of the play-to-earn movement by offering multiple modes of play. In BOG gameplay, players can battle in Player vs. Environment (PvE), Player vs. Player (PvP), or Tournament modes, using their collection of NFT avatars. With a tiered system of playable NFTs, a variety of gaming modes, and a rewards model in place, BOG will become the go-to platform for players to test their skills and agility while earning rewards in-game.

A unique feature of BOG’s NFT structure is the ability for players to rent NFTs, which adds yet another revenue stream for players looking to leverage the BOG ecosystem. Owners of specific NFTs can rent their assets out to players who are eager to play the game, but do not yet want to commit to purchasing their own asset. By implementing this mechanism, both established players and inquisitive newcomers can earn increased in-game rewards, maximizing the utility of the NFTs featured in the BOG game.

To further incentivize players for continued gameplay and reward players for remarkable in-game achievements, Battle of Guardians will feature two tokens: the Battle of Guardians Share token (BGS) and the Fighting Points token (FP). Both tokens will be utilized within the game’s various modes for purchasing NFT characters and in-game assets, whereas BGS can uniquely be leveraged as a governance token to contribute to the development of the game. Players will also have the ability to stake their BGS tokens to generate additional yield and further their involvement in the BOG ecosystem.

AscendEX is excited to debut the trading of the BGS token and support the growth of the play-to-earn GameFi Ecosystem.

###

About AscendEX
AscendEX is a global cryptocurrency financial platform servicing more than one million institutional and retail traders with the resources needed to obtain more value from their crypto investments. Operating at the nexus of centralized finance and decentralized finance, AscendEX’s platform features access to margin, futures, and spot trading, a robust wallet infrastructure, and staking support for over 200 industry-leading blockchain projects, all producing industry-leading yields and returns, further driving the growth of the crypto ecosystem. In efforts to cultivate scalable and secure forms of decentralized financing, AscendEX has emerged as a leading platform by ROI on its “initial exchange offerings” through supporting some of the industry’s most innovative projects from the DeFi ecosystem. 

To learn more about how AscendEX leverages best practices from both Wall Street and the cryptocurrency ecosystem to extract the highest value per dollar to its users, please visit:

Website: https://ascendex.com
Twitter: https://twitter.com/AscendEX_Global
Telegram: https://t.me/AscendEXEnglish
Medium: https://medium.com/ascendex
 
About Battle of Guardians
Battle of Guardians is a real-time multiplayer NFT Fighting Game that allows players to utilize their NFT asset as Fighters in the battlefield. Battle of Guardians is multiplayer ready, built by a game studio with 7+ years of experience. 
 
For more information and updates, please visit:
 
Website: https://battleofguardians.com/
Twitter: https://twitter.com/BOG_Official_  
Telegram: https://t.me/battleofguardianschat

Attachment

• AscendEX Lists Battle of Guardians Share Token (BGS)

Marketing Dept
AscendEX
marketing@ascendex.com

SOURCE : AscendEX

MARY KAY CONTINUES ITS COMMITMENT TO SKIN SCIENCE

^{Dr. Lucy Gildea, Mary Kay Chief Innovation Officer, Product and Science (Photo: Mary Kay Inc.)}


Mary Kay Presents Research At Two Prestigious Conferences: At The 19^th Aesthetic & Anti-Aging Medicine World Congress (AMWC) And At The European Society For Dermatological Research (ESDR)


DALLAS, Jan 14 (Bernama-BUSINESS WIRE) -- Mary Kay Inc., one of the world’s innovative skincare companies, participated at two renowned European conferences in late 2021. At the 19^th Aesthetic & Anti-Aging Medicine World Congress, Mary Kay Inc. submitted a scientific poster on the usage and tolerability of a highly concentrated retinol formula in Asian skin. Mary Kay Inc. also partnered with the European Society’s Dermatological Research (ESDR) in sponsoring Future Leaders in Dermatology Symposium at their 50^th Annual conference. At this conference, Mary Kay Inc. shared the results of a recent clinical study that demonstrated the capability of a cosmetic formulation to alleviate symptoms associated with sensitive skin.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005071/en/

 

The 19^th Aesthetic & Anti-Aging Medicine World Congress took place from September 16-18, 2021, in Monte Carlo and was held under the High Patronage of H.S.H. Prince Albert II of Monaco. Attendees of this conference extended to several professions including dermatologists, plastic and cosmetic surgeons, anti-aging doctors, and aesthetic and general practitioners. Over 8,300 participants from 130 countries joined the conference, both in-person and virtually. The digital platform offered an immersive virtual experience that complemented the physical show allowing attendees to join the digital exhibition and watch workshops regardless of the distance or travel restrictions.

Mary Kay scientists were proud to share their latest research on retinol use and tolerability at this conference. By using a gradual retinization protocol on Asian individuals, there was an improvement in their overall skin appearance as well as a reduction in post-inflammatory hyperpigmentation - a common concern when using retinol, especially in skin of color.

“Retinol is a gold-standard skincare ingredient with many proven benefits, but the experience and tolerability of a retinol product are not the same for every person. For individuals who are concerned about potential irritation or hyperpigmentation, the results of this study offer potential solutions. I am very excited to share this research with the scientific community worldwide at AMWC’s 19^th World Congress to share our innovative research with professionals in skin science and aging,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay Inc.

“AMWC 2021 featured a multi-faceted aesthetic and anti-aging medicine program aimed at promoting high-level continued education and we were happy to have Mary Kay participate this year. We hope that we have succeeded in helping to inspire the exchange of new ideas and the sharing of ‘know-how’ in this field on a global level”, said Catherine Decuyper, EuroMediCom Founder and President. “I am grateful to our team, our global partners, the attendees, and the scientific community at large for their contributions and for the opportunity to serve them and their aesthetic and anti-aging medicine needs.”

Following the success of AMWC 2021, EuroMediCom will host AMWC 2022 from March 31 to April 2, 2022, in a hybrid format again in order to allow delegates from across the world to join them for the 20^th edition of their world-leading aesthetic and anti-aging medicine congress. Registrants can choose to attend in person or watch live-streamed sessions from anywhere in the world.

The annual European Society’s Dermatological Research (ESDR) Conference is held in Europe each year every September. In 2021, due to travel restrictions and COVID-19 precautions, the annual meeting took place entirely virtually from September 22-25, 2021. ESDR supports investigative dermatology with the goal of improving the health of patients who are suffering from various skin and infectious diseases and immune disorders. In addition to presenting research, Mary Kay was also able to sponsor a Future Leaders in Dermatology symposium that kicked off the conference.

Associate Principal Scientist Geetha Kalahasti at Mary Kay Inc. shared the results of a recent clinical study that evaluated the effects of a new formulation that contained a blend of lipids identical to the skin's natural ratio, a nociceptor (TRPV-1) antagonist, and a botanical extract that reduces the expression of proinflammatory cytokines.

“At Mary Kay, we are committed to understanding skin biology and designing new products that address skin needs. One ongoing area of focus has been the relationship between sensitive skin and skin barrier function,” said Kalahasti. “Each of these materials targeted a specific biological pathway that contributes to skin redness. The findings revealed that this multi-faceted approach helps strengthen the compromised skin barrier and alleviate discomfort associated with sensitive skin.”

“On behalf of the ESDR board, we would like to thank Mary Kay for the support of the ESDR and the generous contribution to ESDR activities. One of the most important activities of our Society is to promote the presentation of new research data and ideas, and we are delighted to have Mary Kay be a part of this event,” said Leopold Eckhart, Chair, Scientific Program Committee of ESDR.

This particular symposium helps connect young researchers with renowned scientists in dermatology and encourages such collaborations – a focus that is very important to Mary Kay Inc.

ABOUT MARY KAY

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.

ABOUT EUROMEDICOM

EuroMediCom, created in 1999 and part of Informa Exhibitions since 2010, is dedicated to promoting Life Sciences and knowledge through educational Trainings, Conferences & Exhibitions. The main event, AMWC was created in 2003 and has since become the largest and leading medical aesthetic congress in the world. AMWC was developed with the strong belief that external aesthetic treatments and internal aging prevention could be comprehensively addressed by integrating two aspects: aesthetics strategy through dermatology and surgery procedures for external appearance and anti-aging medicine for prevention of aging and enhancement of aesthetic treatments. For more information about AMWC, click here: https://www.euromedicom.com/en/home.html

ABOUT THE EUROPEAN SOCIETY DERMATOLOGICAL RESEARCH (ESDR)

The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to an in-depth understanding of skin homeostasis and towards improving the health of patients suffering from skin and venereal disease, infectious diseases, and immune-mediated and inflammatory disorders. The ESDR facilitates exchange of information relevant to investigative dermatology between clinicians and scientists worldwide. The ESDR also organizes educational events throughout the year to further knowledge in dermatological research. For more information, please visit: https://esdr.org/

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20220113005071/en/

Contact

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

Source : Mary Kay Inc.

FPT SOFTWARE RECOGNIZED IN 2021 GARTNER PEER INSIGHTS™ 'VOICE OF THE CUSTOMER': ROBOTIC PROCESS AUTOMATION

 

FPT Software recognized in 2021 Gartner Peer Insights 'Voice of the Customer': Robotic Process Automation (Photo: Business Wire) 

HANOI, Vietnam, Jan 12 (Bernama-BUSINESS WIRE) -- Vietnam’s leading ICT firm FPT Software has recently been named a Strong Performer in 2021 Gartner Peer Insights™ ‘Voice of the Customer’: Robotic Process Automation (RPA) report. Accordingly, FPT Software received 100 percent “willingness to recommend” from existing customers for deploying its comprehensive RPA platform akaBot. The company has its overall rating ranked second among the recognized vendors.  
 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111006177/en/ 

Published on December 31, 2021, Gartner Peer Insights™ ‘Voice of the Customer’: Robotic Process Automation “is a document that synthesizes Gartner Peer Insights’ reviews into insights for IT decision makers. This aggregated peer perspective, along with the individual detailed reviews, is complementary to Gartner expert research and can play a key role in your buying process, as it focuses on direct peer experiences of implementing and operating a solution. In this document, only vendors with 20 or more eligible published reviews during the specified 18-month submission period are included.”

FPT Software received many positive feedbacks from its customers working in baking & finance, services, retail, utilities, and other industries across the Asia Pacific and North America regions. According to the reviews in the last 12 months, FPT Software provides a “really smart, easy to use and flexible”(¹) automation tool, supported by “a dedicated team with high professional knowledge of RPA and technology”^(²). The company had an overall rating of 4.6 out of 5.0 based on 28 reviews as of October 2021, showing high satisfaction of customers with its product and service.

“We are honored to be recognized by renowned analyst firm Gartner® among global RPA vendors. We believe this is an acknowledgement of our efforts in becoming a global end-to-end IT services provider”, said FPT Software Chief Operating Officer Tran Dang Hoa.

“Amid the urge of digital transformation, we have assisted over 300 companies in optimizing their business with the power of RPA. I’m confident that with our technical know-how and dynamic talent pool, we can help more organizations stay lean, smart and competitive in disruptive times”, he added. 

http://mrem.bernama.com/viewsm.php?idm=42125

MADISON REALTY CAPITAL ORIGINATES $345 MILLION LOAN FOR ST. REGIS RESIDENCES ON BOSTON WATERFRONT

NEW YORK, Jan 14 (Bernama-GLOBE NEWSWIRE) -- Madison Realty Capital, a vertically integrated real estate private equity firm focused on debt and equity investment strategies, today announced that it has originated a $345 million loan to Cronin Development for the completion of a 22-story, 114-unit residential and retail condominium development at 150 Seaport Boulevard in Boston, Massachusetts.

The property will contain a mix of one-bedroom to six-bedroom penthouse residences with waterfront views, a majority of which will feature outdoor space, and 10,211 square feet of retail. The Residences will feature a full range of amenities, including a fitness and wellness center with a spa and jacuzzi, bistro-style restaurant with waterfront dining, a grand lounge and pool overlooking the harbor, boardroom, business center, catering kitchen, and two guest suites, all managed by St. Regis residential staff.

Josh Zegen, Managing Principal and Co-Founder of Madison Realty Capital, said “Boston’s Seaport District is expanding rapidly, but high barriers to entry and long entitlement processes have constrained the supply of luxury condominium offerings. We are pleased to expand our presence in Boston to deliver an attractive and complex financing solution mid-construction for a significantly presold property to Cronin Development, a developer with over twenty years of experience developing and managing real estate projects in the Boston area. This transaction reflects Madison Realty Capital’s ability to deliver unique financing and certainty of execution for residential projects in every phase of development.”

Jon Cronin, Founder of Cronin Development, said “We are thrilled to engage Madison Realty Capital as a single source of financing to complete this luxury residential product, which will be the last waterfront residential development in the Seaport District. Madison Realty Capital was able to leverage its knowledge of the Boston condominium market to quickly and efficiently provide us a tailored financing solution during the construction process that will enable us to complete the project in the near term.”

Madison Realty Capital has significant experience investing in Boston. Notable transactions include a $165 million loan to Scape North America for the development of a 451-unit multifamily project in Boston’s Fenway neighborhood and a $314 million construction loan to Raffles Boston Back Bay Hotel & Residences.

About Madison Realty Capital 

Madison Realty Capital is a vertically integrated real estate private equity firm that, as of December 31, 2021, manages approximately $8 billion in total assets on behalf of a global institutional investor base. Since 2004, Madison Realty Capital has completed approximately $20 billion in transactions providing borrowers with flexible and highly customized financing solutions, strong underwriting capabilities, and certainty of execution. Headquartered in New York City, with an office in Los Angeles, the firm has approximately 70 employees across all real estate investment, development, and property management disciplines. Madison Realty Capital has been frequently named to the Commercial Observer’s prestigious “Power 100” list of New York City real estate players and is consistently cited as a top construction lender, among other industry recognitions. To learn more, follow us on LinkedIn and visit www.madisonrealtycapital.com.

Nathaniel Garnick/Grace Cartwright
Gasthalter & Co.
+1 (212) 257 4170
madisonrealty@gasthalter.com

SOURCE : Madison Realty Capital

Cellebrite Wins Significant Open-Source Intelligence Solutions Customer Contract

 

New deal reinforces Cellebrite’s market leadership as law enforcement organizations preferred end-to-end technology partner to modernize their entire investigative workflow

PETAH TIKVA, Israel and TYSONS CORNER, Va., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Cellebrite (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced that it has won a significant Open-Source Intelligence (“OSINT”) customer contract following the Company’s acquisition of Digital Clues in November 2021. The new customer contract is a multi-year contract with initial value of US$1.5 million for the first year and is the most noteworthy SaaS deal for Cellebrite to date.

Cellebrite’s OSINT solution, part of the Company’s industry leading investigative DI Platform, is aimed at supporting the early stages of law enforcement investigations, irrespective of whether the investigative teams have a lead or not, by quickly enabling them to collect and connect large amounts of fragmented digital evidence from many dynamic sources, including the surface web, deep web, and dark web. The adoption of the OSINT solution is being driven by its use by law enforcement agencies as they increase their efforts to stop crimes against children, drug and human trafficking, organized crime, and terrorism. The new customer selected Cellebrite’s OSINT solutions to replace its existing system because of the OSINT solutions’ unmatched capabilities, ability to adapt quickly to rapidly changing open-source repositories, and ease of use.

“We are pleased with the early success reflected by this significant, multi-year contract that demonstrates our ability to provide end-to-end investigative workflow solutions to law enforcement which help to make our communities safer,” said Alon Klomek, Cellebrite’s Chief Business Officer. “With our scalable and innovative cloud offerings, Cellebrite is able to partner with law enforcement agencies to address their growing demand for solutions that kickstart their investigation efforts by legally and ethically collecting open-source data in criminal investigations.”

About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com and https://investors.cellebrite.com.

Caution Regarding Forward Looking Statements

This document includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the business of Cellebrite are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: Cellebrite’s ability to develop technologically advanced solutions and successfully integrate with the software solutions used by customers; acceptance of solutions by customers; errors, failures, defects or bugs in solutions; a failure to maintain sales and marketing personnel productivity or hire, integrate and retain additional sales and marketing personnel; the impact of the global COVID-19 pandemic; the impact of competition on pricing and on Cellebrite’s market share; sub-optimal results from products due to misuse by customers; Cellebrite’s failure to maintain and enhance its reputation and brand; inaccuracy of the estimates of Cellebrite’s market opportunity and forecasts of market growth; changes to packaging and licensing models that adversely affect the ability to attract or retain customers; failure to manage future growth effectively; failure to introduce new solutions and add-ons; issues in the use of artificial intelligence resulting in reputational harm or liability; the need for additional capital to support the growth of Cellebrite’s business; a failure to maintain the security of operations and the integrity of software solutions; the impact of government budgeting cycles and appropriations, early termination, audits, investigations, sanctions and penalties; a decline in government budgets, changes in spending or budgetary priorities, or delays in contract awards; a failure to adequately obtain, maintain, protect and enforce Cellebrite’s intellectual property or infringement of the intellectual property rights of others; perceptions or court or regulatory decisions that Cellebrite’s solutions violate privacy rights; the use of solutions by customers in a way that is, or that is perceived to be, incompatible with human rights; failure to comply with laws regarding privacy, data protection and security, technology protection, sanctions, export controls and other matters; and other factors, risks and uncertainties set forth in the sections titled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the final proxy statement/prospectus relating to Cellebrite’s consummated business combination filed with the SEC on August 5, 2021 and in other documents filed by Cellebrite with the SEC, which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Media        
Adam Jaffe
VP of Global Communications
+1 973 206 7643
adam.jaffe@cellebrite.com – or –
RapidResponse@cellebrite.com

Investors
Anat Earon-Heilborn
VP Investor Relations
+972 73 394 8440
investors@cellebrite.com

SOURCE: Cellebrite DI Ltd

 

PT Asuransi Jasa Indonesia Credit Ratings downgraded - AM Best

KUALA LUMPUR, Jan 10  -- Global credit rating agency, AM Best has removed from under review with negative implications and downgraded the Financial Strength Rating (FSR) to C (Weak) from B (Fair) and the Long-Term Issuer Credit Rating (Long-Term ICR) to ‘ccc+’ (Weak) from ‘bb+’ (Fair) of PT Asuransi Jasa Indonesia (Asuransi Jasindo) Indonesia.

The outlook assigned to the FSR is stable while the outlook assigned to the Long-Term ICR is negative.

These Credit Ratings (ratings) reflect Asuransi Jasindo’s balance sheet strength, which AM Best assesses as weak, as well as its marginal operating performance, neutral business profile and marginal enterprise risk management (ERM).

The ratings of Asuransi Jasindo were placed under review with negative implications on May 19, 2021, following a significant deterioration in the company’s underwriting performance emanating from its credit insurance business. 

On July 8, 2021, the ratings were downgraded and maintained under review with negative implications, following a delay in the finalisation of the company’s 2020 audited financial statements and AM Best’s increased concern over the loss exposure from the company’s credit insurance business.

Based on a statement, the latest rating actions follow the finalisation of the company’s 2020 audited financial statements, which included restatements of prior financial years.

The company’s latest financial position shows a significant capital erosion from outsized losses in its credit insurance business. The rating downgrades reflect a weakening of AM Best’s view of Asuransi Jasindo’s balance sheet strength and operating performance fundamentals.

The negative outlook of the Long-Term ICR reflects AM Best’s expectation of continued pressure on the company’s balance sheet strength, operating performance and ERM fundamentals over the intermediate term.

While Asuransi Jasindo’s management team continues to implement a turnaround strategy aimed at restoring capital adequacy and improving prospective operating performance, significant execution and downside risks remain at present.

For more information, visit www.ambest.com.

-- BERNAMA 

Dr John Orloff Designated To Zenas Biopharma Board Of Directors

KUALA LUMPUR, Jan 7 -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies, has announced the appointment of John Orloff, MD to its Board of Directors.

Dr Orloff joins the Zenas Board with over 25 years of experience successfully leading global research and development organisations across multiple therapeutic areas including autoimmune diseases.

“We are extremely pleased to welcome Dr Orloff to the Zenas Board of Directors,” said Lonnie Moulder, Founder and Executive Chairman of Zenas in a statement.

“John’s leadership and extensive expertise in research, development, and medical and regulatory affairs will be invaluable as we advance our portfolio of innovative immune-based therapeutics and continue to expand our pipeline via business development.”

Meanwhile, Dr Orloff said: “I am delighted to work with the Zenas leadership team and fellow directors as the Company rapidly progresses an exciting immune-based pipeline. I look forward to contributing to the Company’s continued development as it strives to deliver on its mission to bring innovative medicines to patients in need.”

He currently serves as a venture partner with Agent Capital. In his most recent executive role, he served as Executive Vice President and Head of Research and Development at Alexion where his leadership in expanding the development pipeline to 30 programs supported the recent US$39 billion acquisition of Alexion by AstraZeneca. (US$1 = RM4.213)

Before entering the biopharmaceutical industry, Dr Orloff was a faculty member of the Yale University School of Medicine.

He received an undergraduate degree in chemistry from Dartmouth College, earned his medical degree from the University of Vermont, College of Medicine and completed a fellowship in endocrinology and metabolism at Yale University School of Medicine.

For more information on Zenas BioPharma, visit www.zenasbio.com.

-- BERNAMA